INMB (INmune Bio) Moat Score: 3/10 (As of Jun. 28, 2026)


INMB INmune Bio Inc INMB
52 GF Score
Price $1.42
GF Value $1.83
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is INmune Bio Moat Score?

INmune Bio INMB -5.02% 52 Moat Score is 3 as of Jun. 28, 2026. GuruFocus rates INMB with a GF Score™ of 52/100 and a GF Value™ of $1.83 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,402 Biotechnology companies, INmune Bio ranks better than 75.46% on this metric.

INmune Bio has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

INmune Bio has No Moat: INmune Bio Inc operates in a competitive biotech space with limited market leadership. The company lacks significant network effects, customer switching costs, and brand strength. Its intellectual property and R&D efforts are not yet sufficient to establish a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes INmune Bio might have No Moat - Very weak/transient advantages.

INmune Bio  (NAS:INMB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

INmune Bio Moat Score Related Terms

INMB vs GRDX, VERU, ABVC: Moat Score Comparison

For the Biotechnology subindustry, INmune Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where INmune Bio's Moat Score falls into.


INMB
52GF Score
INmune Bio Inc INMB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
INmune Bio (INMB) has a Moat Score of 3 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, INmune Bio ranks #344 out of 1402 companies in the Biotechnology industry, placing it in the top 24.5%.
Is INmune Bio's Moat Score too high?
INmune Bio's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. INmune Bio's value of 3 is 50% above this industry median. Based on the distribution chart, INmune Bio ranks #344 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, INmune Bio has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Moat Score compare to GRDX and VERU?
According to the Biotechnology industry distribution chart, INmune Bio ranks #344 out of 1402 companies for Moat Score. This places INmune Bio in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. INmune Bio's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. INmune Bio's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.83, compared to a current price of $1.42 — trading 22.4% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. INmune Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For INmune Bio (INMB), the current Moat Score is 3 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.42 is trading 22.4% below its estimated GF Value™ of $1.83. GuruFocus considers INmune Bio to be Modestly Undervalued.

Key valuation signals for INMB:

  • Moat Score: 3
  • GF Value™: $1.83 vs. price of $1.42 (22.4% below fair value)
  • GF Score™: 52/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#344 of 1402)

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score

Get the complete analysis for INMB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.42
Price
$1.83
GF Value